Romosozumab as a Treatment for Osteoporosis: Predictors of Efficacy at 12 Months

被引：0
|
作者：
Hirano, Yuji [1 ]
Ohno, Yusuke [1 ]
机构：
[1] Toyohashi Municipal Hosp, Rheumatol, Toyohashi, Aichi, Japan
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-582
引用
收藏
页码：272 / 273
页数：2
相关论文
共 50 条
  • [31] Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl, Katharina
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2020, 170 (5-6) : 124 - 131
  • [32] Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
    Khanjee, Naveed
    Maalouf, Naim M.
    [J]. JOURNAL OF THE ENDOCRINE SOCIETY, 2022, 6 (12)
  • [33] Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study
    Kobayakawa, Tomonori
    Miyazaki, Akiko
    Takahashi, Jun
    Nakamura, Yukio
    [J]. BONE, 2022, 162
  • [34] Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis
    Ebina, Kosuke
    Etani, Yuki
    Tsuboi, Hideki
    Nagayama, Yoshio
    Kashii, Masafumi
    Miyama, Akira
    Kunugiza, Yasuo
    Hirao, Makoto
    Okamura, Gensuke
    Noguchi, Takaaki
    Takami, Kenji
    Goshima, Atsushi
    Miura, Taihei
    Fukuda, Yuji
    Kurihara, Takuya
    Okada, Seiji
    Nakata, Ken
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (11) : 2441 - 2443
  • [35] Effects of Romosozumab in Postmenopausal Women With Osteoporosis After 2 and 12 Months Assessed by MicroCT on Iliac Crest Bone Biopsies.
    Roux, Jean-Paul
    Chavassieux, Pascale
    Chapurlat, Roland
    Portero-Muzy, Nathalie
    Garcia, Pedro
    Brown, Jacques P.
    Libanati, Cesar
    Boyce, Rogely
    Wang, Andrea
    Grauer, Andreas
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S380 - S380
  • [36] Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
    Ebina, K.
    Etani, Y.
    Tsuboi, H.
    Nagayama, Y.
    Kashii, M.
    Miyama, A.
    Kunugiza, Y.
    Hirao, M.
    Okamura, G.
    Noguchi, T.
    Takami, K.
    Goshima, A.
    Miura, T.
    Fukuda, Y.
    Kurihara, T.
    Okada, S.
    Nakata, K.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (08) : 1807 - 1813
  • [37] Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
    K. Ebina
    Y. Etani
    H. Tsuboi
    Y. Nagayama
    M. Kashii
    A. Miyama
    Y. Kunugiza
    M. Hirao
    G. Okamura
    T. Noguchi
    K. Takami
    A. Goshima
    T. Miura
    Y. Fukuda
    T. Kurihara
    S. Okada
    K. Nakata
    [J]. Osteoporosis International, 2022, 33 : 1807 - 1813
  • [38] Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis
    Kosuke Ebina
    Yuki Etani
    Hideki Tsuboi
    Yoshio Nagayama
    Masafumi Kashii
    Akira Miyama
    Yasuo Kunugiza
    Makoto Hirao
    Gensuke Okamura
    Takaaki Noguchi
    Kenji Takami
    Atsushi Goshima
    Taihei Miura
    Yuji Fukuda
    Takuya Kurihara
    Seiji Okada
    Ken Nakata
    [J]. Osteoporosis International, 2022, 33 : 2441 - 2443
  • [39] Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study
    A. Tominaga
    K. Wada
    K. Okazaki
    H. Nishi
    Y. Terayama
    Y. Kato
    [J]. Osteoporosis International, 2021, 32 : 1999 - 2009
  • [40] Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study
    Tominaga, A.
    Wada, K.
    Okazaki, K.
    Nishi, H.
    Terayama, Y.
    Kato, Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (10) : 1999 - 2009
12345